Published in Nat Rev Gastroenterol Hepatol on April 01, 2009
Activation of natural killer cells during acute infection with hepatitis C virus. Gastroenterology (2010) 1.37
Persistent hepatitis C virus infections and hepatopathological manifestations in immune-competent humanized mice. Cell Res (2014) 1.13
Genomic scale analysis of racial impact on response to IFN-alpha. Proc Natl Acad Sci U S A (2009) 1.08
Common threads in persistent viral infections. J Virol (2009) 0.93
Mixing the right hepatitis C inhibitor cocktail. Trends Mol Med (2010) 0.91
The evolution of the major hepatitis C genotypes correlates with clinical response to interferon therapy. PLoS One (2009) 0.91
Viperin is highly induced in neutrophils and macrophages during acute and chronic lymphocytic choriomeningitis virus infection. J Immunol (2010) 0.90
Targeting the inflammation in HCV-associated hepatocellular carcinoma: a role in the prevention and treatment. J Transl Med (2010) 0.88
Host genetic basis for hepatitis C virus clearance: a role for blood collection centers. Curr Opin Hematol (2010) 0.87
Antigenic cooperation among intrahost HCV variants organized into a complex network of cross-immunoreactivity. Proc Natl Acad Sci U S A (2015) 0.85
Genetic variation in the interleukin-28B gene is associated with spontaneous clearance and progression of hepatitis C virus in Moroccan patients. PLoS One (2013) 0.85
Vinexin β Interacts with Hepatitis C Virus NS5A, Modulating Its Hyperphosphorylation To Regulate Viral Propagation. J Virol (2015) 0.78
Regulation of host innate immunity by hepatitis C virus: crosstalk between hepatocyte and NK/DC. Rev Infect (2010) 0.77
HCV-Induced Oxidative Stress: Battlefield-Winning Strategy. Oxid Med Cell Longev (2016) 0.75
A novel approach to identify candidate prognostic factors for hepatitis C treatment response integrating clinical and viral genetic data. Evol Bioinform Online (2015) 0.75
What is the Risk of Graft Reinfection in Case of Liver Transplantation for Patients With Acute HEV or HAV Infection? J Clin Exp Hepatol (2016) 0.75
Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med (2005) 21.56
Complete replication of hepatitis C virus in cell culture. Science (2005) 18.59
Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science (2005) 16.84
Global epidemiology of hepatitis C virus infection. Lancet Infect Dis (2005) 16.44
Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A (2005) 14.78
Binding of hepatitis C virus to CD81. Science (1998) 12.40
Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A (2003) 11.65
Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature (2007) 9.52
Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. Biochem J (2001) 9.40
Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci U S A (2008) 8.56
Replication of hepatitis C virus. Nat Rev Microbiol (2007) 8.31
Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science (1996) 8.29
HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science (2004) 8.22
Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci U S A (2003) 8.21
Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature (2009) 8.05
Intracellular pattern recognition receptors in the host response. Nature (2006) 8.04
The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J (2002) 7.93
Interferon modulation of cellular microRNAs as an antiviral mechanism. Nature (2007) 7.04
Cellular cofactors affecting hepatitis C virus infection and replication. Proc Natl Acad Sci U S A (2007) 6.79
Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc Natl Acad Sci U S A (2005) 6.64
Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science (1999) 6.21
Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J Virol (1992) 6.09
Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc Natl Acad Sci U S A (2002) 5.81
Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling. Proc Natl Acad Sci U S A (2005) 5.64
Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity. Proc Natl Acad Sci U S A (2005) 5.31
Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology (1997) 5.26
HCV persistence and immune evasion in the absence of memory T cell help. Science (2003) 5.23
Gene regulation by transcription factors and microRNAs. Science (2008) 5.07
Lack of protective immunity against reinfection with hepatitis C virus. Science (1992) 4.94
Viral and therapeutic control of IFN-beta promoter stimulator 1 during hepatitis C virus infection. Proc Natl Acad Sci U S A (2006) 4.84
Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med (1996) 4.61
Evasion of intracellular host defence by hepatitis C virus. Nature (2005) 4.58
Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor. J Biol Chem (2003) 4.58
Internal initiation of translation in eukaryotes: the picornavirus paradigm and beyond. RNA (1995) 4.58
Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection. J Immunol (2002) 4.56
Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins. Virology (1991) 4.47
Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol (2004) 4.12
Decreased levels of microRNA miR-122 in individuals with hepatitis C responding poorly to interferon therapy. Nat Med (2009) 3.72
Cellular determinants of hepatitis C virus assembly, maturation, degradation, and secretion. J Virol (2007) 3.57
Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology (2004) 3.47
Intrahepatic gene expression during chronic hepatitis C virus infection in chimpanzees. J Virol (2004) 3.43
Host factors and failure of interferon-alpha treatment in hepatitis C virus. Hepatology (2004) 2.93
Quantitative analysis of the hepatitis C virus replication complex. J Virol (2005) 2.91
DC-SIGN and L-SIGN are high affinity binding receptors for hepatitis C virus glycoprotein E2. J Biol Chem (2003) 2.82
Dysfunction and functional restoration of HCV-specific CD8 responses in chronic hepatitis C virus infection. Hepatology (2007) 2.78
Hepatitis C virus lacking the hypervariable region 1 of the second envelope protein is infectious and causes acute resolving or persistent infection in chimpanzees. Proc Natl Acad Sci U S A (2000) 2.70
Establishment of B-cell lymphoma cell lines persistently infected with hepatitis C virus in vivo and in vitro: the apoptotic effects of virus infection. J Virol (2003) 2.60
Influence of MHC class II genotype on outcome of infection with hepatitis C virus. The HENCORE group. Hepatitis C European Network for Cooperative Research. Lancet (2000) 2.58
High density lipoproteins facilitate hepatitis C virus entry through the scavenger receptor class B type I. J Biol Chem (2005) 2.31
Replication strategy of Kunjin virus: evidence for recycling role of replicative form RNA as template in semiconservative and asymmetric replication. Virology (1985) 2.30
Visualization of double-stranded RNA in cells supporting hepatitis C virus RNA replication. J Virol (2007) 2.15
Oxidized low-density lipoprotein inhibits hepatitis C virus cell entry in human hepatoma cells. Hepatology (2006) 2.04
Global transcriptional response to interferon is a determinant of HCV treatment outcome and is modified by race. Hepatology (2006) 2.03
Is RNA interference involved in intrinsic antiviral immunity in mammals? Nat Immunol (2006) 2.02
IFN-alpha antagonistic activity of HCV core protein involves induction of suppressor of cytokine signaling-3. FASEB J (2003) 2.00
Regulation of PKR and IRF-1 during hepatitis C virus RNA replication. Proc Natl Acad Sci U S A (2002) 1.96
Viral evolution and interferon resistance of hepatitis C virus RNA replication in a cell culture model. J Virol (2004) 1.93
Hepatitis C virus nonstructural 5A protein induces interleukin-8, leading to partial inhibition of the interferon-induced antiviral response. J Virol (2001) 1.92
Broadly neutralizing human monoclonal antibodies to the hepatitis C virus E2 glycoprotein. J Gen Virol (2008) 1.91
Hepatitis C virus inhibits interferon signaling through up-regulation of protein phosphatase 2A. Gastroenterology (2004) 1.91
Binding of the hepatitis C virus E2 glycoprotein to CD81 is strain specific and is modulated by a complex interplay between hypervariable regions 1 and 2. J Virol (2003) 1.89
Lack of response to exogenous interferon-alpha in the liver of chimpanzees chronically infected with hepatitis C virus. Hepatology (2007) 1.84
Hepatitis C virus (HCV) core protein-induced, monocyte-mediated mechanisms of reduced IFN-alpha and plasmacytoid dendritic cell loss in chronic HCV infection. J Immunol (2006) 1.82
Hepatitis C virus non-structural proteins in the probable membranous compartment function in viral genome replication. J Biol Chem (2003) 1.77
Elevated levels of interleukin-8 in serum are associated with hepatitis C virus infection and resistance to interferon therapy. J Virol (2001) 1.74
The neutralizing activity of anti-hepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein. J Virol (2007) 1.69
Infection and dysfunction of circulating blood dendritic cells and their subsets in chronic hepatitis C virus infection. J Gastroenterol (2004) 1.68
Viral determinants of resistance to treatment in patients with hepatitis C. Clin Microbiol Rev (2007) 1.65
Pervasive influence of hepatitis C virus on the phenotype of antiviral CD8+ T cells. J Immunol (2004) 1.64
Identification and in vitro expansion of functional antigen-specific CD25+ FoxP3+ regulatory T cells in hepatitis C virus infection. J Virol (2008) 1.63
Nonstructural protein precursor NS4A/B from hepatitis C virus alters function and ultrastructure of host secretory apparatus. J Virol (2003) 1.62
Intrahepatic CD8+ T-cell failure during chronic hepatitis C virus infection. Hepatology (2005) 1.61
Hepatitis C virus mutation affects proteasomal epitope processing. J Clin Invest (2004) 1.58
Higher clearance of hepatitis C virus infection in females compared with males. Gut (2006) 1.57
L-SIGN (CD209L) and DC-SIGN (CD209) mediate transinfection of liver cells by hepatitis C virus. Proc Natl Acad Sci U S A (2004) 1.48
Interferon alpha decreases expression of human scavenger receptor class BI, a possible HCV receptor in hepatocytes. Gut (2007) 1.46
Activation of endoplasmic reticulum stress response by hepatitis viruses up-regulates protein phosphatase 2A. Hepatology (2007) 1.44
Compartmentalization of hepatitis C virus genotypes between plasma and peripheral blood mononuclear cells. J Virol (2005) 1.41
Double-stranded RNA-activated protein kinase mediates virus-induced apoptosis: a new role for an old actor. Proc Natl Acad Sci U S A (1999) 1.40
Scavenger receptor BI: a scavenger receptor with a mission to transport high density lipoprotein lipids. Curr Opin Lipidol (2004) 1.37
Activation and evasion of the antiviral 2'-5' oligoadenylate synthetase/ribonuclease L pathway by hepatitis C virus mRNA. RNA (2002) 1.36
TBC1D20 is a Rab1 GTPase-activating protein that mediates hepatitis C virus replication. J Biol Chem (2007) 1.36
Presence of functional dendritic cells in patients chronically infected with hepatitis C virus. Blood (2003) 1.33
Comparable functions of plasmacytoid and monocyte-derived dendritic cells in chronic hepatitis C patients and healthy donors. J Hepatol (2005) 1.27
Virological and immunological determinants of intrahepatic virus-specific CD8+ T-cell failure in chronic hepatitis C virus infection. Hepatology (2008) 1.24
Peripheral virus-specific T-cell interleukin-10 responses develop early in acute hepatitis C infection and become dominant in chronic hepatitis. J Hepatol (2008) 1.22
Functional properties of a monoclonal antibody inhibiting the hepatitis C virus RNA-dependent RNA polymerase. J Biol Chem (2001) 1.19
HCV core protein interaction with gC1q receptor inhibits Th1 differentiation of CD4+ T cells via suppression of dendritic cell IL-12 production. J Leukoc Biol (2007) 1.17
Comparison between subgenomic replicons of hepatitis C virus genotypes 2a (JFH-1) and 1b (Con1 NK5.1). Intervirology (2006) 1.14
Myeloid dendritic cells of patients with chronic HCV infection induce proliferation of regulatory T lymphocytes. Gastroenterology (2008) 1.11
Age-related response to interferon alfa treatment in women vs men with chronic hepatitis C virus infection. Arch Intern Med (1998) 1.11
Blocking of monocyte-associated B7-H1 (CD274) enhances HCV-specific T cell immunity in chronic hepatitis C infection. J Leukoc Biol (2007) 1.11
A Rab-GAP TBC domain protein binds hepatitis C virus NS5A and mediates viral replication. J Virol (2007) 1.08
Effects of mutation in hepatitis C virus nonstructural protein 5A on interferon resistance mediated by inhibition of PKR kinase activity in mammalian cells. Microbiol Immunol (2001) 1.07
Dynamics of hepatitis C virus replication in human liver. Am J Pathol (2003) 1.05
Modulation of the peripheral T-Cell response by CD4 mutants of hepatitis C virus: transition from a Th1 to a Th2 response. Hum Immunol (2003) 1.03
Compartmentalization of hepatitis C virus quasispecies in blood mononuclear cells of patients with mixed cryoglobulinemic syndrome. J Virol (2005) 0.99
Six RNA viruses and forty-one hosts: viral small RNAs and modulation of small RNA repertoires in vertebrate and invertebrate systems. PLoS Pathog (2010) 2.62
Discovery of a hepatitis C target and its pharmacological inhibitors by microfluidic affinity analysis. Nat Biotechnol (2008) 2.52
Structural linkage between ligand discrimination and receptor activation by type I interferons. Cell (2011) 2.39
Amphipathic helix-dependent localization of NS5A mediates hepatitis C virus RNA replication. J Virol (2003) 2.20
An N-terminal amphipathic helix in hepatitis C virus (HCV) NS4B mediates membrane association, correct localization of replication complex proteins, and HCV RNA replication. J Virol (2004) 1.99
The effect of donor race on the survival of Black Americans undergoing liver transplantation for chronic hepatitis C. Liver Transpl (2009) 1.64
Prevalence, correlates, and viral dynamics of hepatitis delta among injection drug users. J Infect Dis (2010) 1.58
A nucleotide binding motif in hepatitis C virus (HCV) NS4B mediates HCV RNA replication. J Virol (2004) 1.41
TBC1D20 is a Rab1 GTPase-activating protein that mediates hepatitis C virus replication. J Biol Chem (2007) 1.36
In vivo antiviral efficacy of prenylation inhibitors against hepatitis delta virus. J Clin Invest (2003) 1.33
Hepatitis C virus core protein associates with detergent-resistant membranes distinct from classical plasma membrane rafts. J Virol (2004) 1.30
A drug-controllable tag for visualizing newly synthesized proteins in cells and whole animals. Proc Natl Acad Sci U S A (2008) 1.29
Identification of a class of HCV inhibitors directed against the nonstructural protein NS4B. Sci Transl Med (2010) 1.20
Isolation and transcriptional profiling of purified hepatic cells derived from human embryonic stem cells. Stem Cells (2008) 1.19
Coinfection with hepatitis B and D: epidemiology, prevalence and disease in patients in Northern California. J Gastroenterol Hepatol (2013) 1.17
A prenylation inhibitor prevents production of infectious hepatitis delta virus particles. J Virol (2002) 1.13
Simplified RNA secondary structure mapping by automation of SHAPE data analysis. Nucleic Acids Res (2011) 1.12
The hepatitis C virus NS5A inhibitor (BMS-790052) alters the subcellular localization of the NS5A non-structural viral protein. Virology (2011) 1.10
Potential for hepatitis C virus resistance to nitazoxanide or tizoxanide. Antimicrob Agents Chemother (2008) 1.09
Development of novel therapies for hepatitis C. Antiviral Res (2010) 1.09
A Rab-GAP TBC domain protein binds hepatitis C virus NS5A and mediates viral replication. J Virol (2007) 1.08
The anti-hepatitis C agent nitazoxanide induces phosphorylation of eukaryotic initiation factor 2alpha via protein kinase activated by double-stranded RNA activation. Gastroenterology (2009) 1.05
Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection. Dig Dis Sci (2014) 1.02
Role for ADP ribosylation factor 1 in the regulation of hepatitis C virus replication. J Virol (2010) 0.97
A small molecule inhibits HCV replication and alters NS4B's subcellular distribution. Antiviral Res (2010) 0.96
The nucleotide binding motif of hepatitis C virus NS4B can mediate cellular transformation and tumor formation without Ha-ras co-transfection. Hepatology (2008) 0.95
Binding dynamics of hepatitis C virus' NS5A amphipathic peptide to cell and model membranes. J Virol (2007) 0.94
Structural map of a microRNA-122: hepatitis C virus complex. J Virol (2011) 0.92
The evolution of the major hepatitis C genotypes correlates with clinical response to interferon therapy. PLoS One (2009) 0.91
Viral infection of human progenitor and liver-derived cells encapsulated in three-dimensional PEG-based hydrogel. Biomed Mater (2008) 0.90
Prenylation inhibitors: a novel class of antiviral agents. J Antimicrob Chemother (2003) 0.89
Transdifferentiation of adipose-derived stem cells into hepatocytes: a new approach. Liver Int (2010) 0.89
Alpha-helical peptide-induced vesicle rupture revealing new insight into the vesicle fusion process as monitored in situ by quartz crystal microbalance-dissipation and reflectometry. Anal Chem (2009) 0.89
The Future of HCV Therapy: NS4B as an Antiviral Target. Viruses (2010) 0.87
Hydrophobic nanoparticles improve permeability of cell-encapsulating poly(ethylene glycol) hydrogels while maintaining patternability. Proc Natl Acad Sci U S A (2010) 0.87
Employing an amphipathic viral peptide to create a lipid bilayer on Au and TiO2. J Am Chem Soc (2007) 0.86
Mechanism of an amphipathic alpha-helical peptide's antiviral activity involves size-dependent virus particle lysis. ACS Chem Biol (2009) 0.85
The hepatitis C virus (HCV) NS4B RNA binding inhibitor clemizole is highly synergistic with HCV protease inhibitors. J Infect Dis (2010) 0.83
Employing two different quartz crystal microbalance models to study changes in viscoelastic behavior upon transformation of lipid vesicles to a bilayer on a gold surface. Anal Chem (2007) 0.83
The reliable targeting of specific drug release profiles by integrating arrays of different albumin-encapsulated microsphere types. Biomaterials (2009) 0.82
Hepatitis d. Curr Treat Options Gastroenterol (2007) 0.82
Isolation of human fetal liver progenitors and their enhanced proliferation by three-dimensional coculture with endothelial cells. Tissue Eng Part A (2008) 0.80
Creation of lipid partitions by deposition of amphipathic viral peptides. Langmuir (2007) 0.80
Viral suppression and cirrhosis regression with tenofovir disoproxil fumarate in Asians with chronic hepatitis B. Dig Dis Sci (2014) 0.79
Screening for esophageal varices in cirrhotic patients: endoscope, platelet count, or both? Gastrointest Endosc (2006) 0.78
The anti-genomic (negative) strand of Hepatitis C Virus is not targetable by shRNA. Nucleic Acids Res (2013) 0.78
The Power of silence: application of small interfering RNAs to gastrointestinal diseases. Gastroenterology (2007) 0.78
Testing antivirals against hepatitis delta virus: farnesyl transferase inhibitors. Methods Mol Med (2004) 0.77
Quantitative Evaluation of Viral Protein Binding to Phosphoinositide Receptors and Pharmacological Inhibition. Anal Chem (2017) 0.75
Hepatitis D in Children. J Pediatr Gastroenterol Nutr (2015) 0.75
Analogs design, synthesis and biological evaluation of peptidomimetics with potential anti-HCV activity. Bioorg Med Chem (2013) 0.75